海外招聘者

	Alexis Thompson （Ann and Robert H. Lurie Children's Hospital of Chicago, USA） ASH Special Lecture： Advances in Gene Therapy for Blood Disorders Symposium9（JSH-ASH Joint Symposium）： Recent advances in bone marrow failure
	Pieter Sonneveld （Department of Hematology, Erasmus MC Cancer Institute, Netherlands） EHA Special Lecture： Recent therapeutic algorithms in Multiple Myeloma Symposium4（JSH-EHA Joint Symposium）： Path to TFR: Role of immune system in CML
	Cortes JE （MD Anderson Cancer Center, USA） Presidential Symposium： Cutting edge of molecular target therapy for hematologic malignancies Educational Lecture EL2-4B
	Hartmut Döhner （Department of Internal Medicine III, Comprehensive Cancer Center Ulm, University Hospital Ulm, Germany） Presidential Symposium： Cutting edge of molecular target therapy for hematologic malignancies “Molecular targeted therapy of acute myeloid leukemia”
	Daniel Pollyea （University of Colorado School of Medicine, USA） Presidential Symposium： Cutting edge of molecular target therapy for hematologic malignancies “Targeting BCL-2 in Chronic Lymphocytic Leukemia and Acute Myeloid Leukemia”
	Katja Weisel （Hematological and Oncological Department, Medical Center University of Tuebingen, Germany） Presidential Symposium： Cutting edge of molecular target therapy for hematologic malignancies “Cutting edge of molecular target therapy for Multiple Myeloma”
	Elaine S. Jaffe （Hematopathology Section, Laboratory of Pathology, CCR, NCI, MD, USA） Symposium1： Pathological diagnosis and clinical management of lymphoproliferative disorders and indolent lymphomas in the era of WHO classification 2016 “Lymphoproliferative disorders and indolent lymphomas of B-cell origin”
	Hermine Olivier　 （Hematology, Paris Descartes University Imagine Institute, France） Symposium1： Pathological diagnosis and clinical management of lymphoproliferative disorders and indolent lymphomas in the era of WHO classification 2016
	Timm Schroeder （D-BSSE, Basel, ETH Zurich, Switzerland） Symposium2： Cell Fate Decision: Intrinsic and extrinsic regulation of hematopoiesis “Long-term single-cell quantification: New tools for old questions”
	Emmanuelle Passegué （Director, Columbia Stem Cell Initiative Alumni Professor of Genetics & Development (in Rehabilitation and Regenerative Medicine) Columbia University Medical Center, USA） Symposium2： Cell Fate Decision: Intrinsic and extrinsic regulation of hematopoiesis
	Marie Ann Scully （Haematology, University College Hospital, UK） Symposium3： Antibody therapy for disorders of thrombosis and hemostasis “Eculizumab for atypical HUS”
	Flora Peyvandi （Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Università degli Studi di Milano, Italy） Symposium3： Antibody therapy for disorders of thrombosis and hemostasis “Caplacizumab for the treatment of acquired thrombotic thrombocytopenic purpura”
	Ingo Roeder （Institute for Medical Informatics and Biometrie (IMB) , Technische Universität Dresden, Faculty of Medicine, Germany） Symposium4（JSH-EHA Joint Symposium）： Path to TFR: Role of immune system in CML “Mathematical Modeling of TKI-Treated Chronic Myeloid Leukemia (CML)”
	Satu Mustjoki （Hematology Research Unit, University of Helsinki, Finland） Symposium4（JSH-EHA Joint Symposium）： Path to TFR: Role of immune system in CML “Immunotherapy of CML and immunological characteristics of therapy response”
	Christian Kratz （Pediatric Hematology and Oncology, Hannover Medical School, Germany） Symposium5： Cancer predisposition and hemato/immunological defect: from children to adults “Cancer Predisposition Syndromes in Children with Cancer”
	Jong Jin Seo （Division of Hematology-Oncology/Department of Pediatrics, Asan Medical Center, Republic, Korea） Symposium5： Cancer predisposition and hemato/immunological defect: from children to adults “Genetic defects of myeloproliferative neoplasms and the predisposition to acute leukemia”
	Catherine M. Bollard （Cancer and Immunology Research, Children's National Medical Center/George Washington University, USA） Symposium6（ISCT Joint Symposium）： New direction of tumor immunotherapy “T-cell Therapies for Leukemia and Lymphoma: Beyond CARs”
	David Gottlieb （Department of Medicine, Westmead Hospital, University of Sydney, Australia） Symposium6（ISCT Joint Symposium）： New direction of tumor immunotherapy “Integrating anti-leukemia and anti-pathogen T-cell therapy in stem cell transplantation”
	Mark Levis （Oncology, Hematologic Malignancies, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, USA） Symposium8： Novel therapeutic strategy for AML “The latest (and greatest?) FLT3 inhibitor”
	Bruno C. Medeiros （Medicine, Stanford University , USA） Symposium8： Novel therapeutic strategy for AML
	Danielle Townsley （The Hematology Branch, NIH, USA） Symposium9（JSH-ASH Joint Symposium）： Recent advances in bone marrow failure “Nontransplant therapy for aplastic anemia”
	Franck Morschhauser （Department of Hematology, University of Lille, France） Symposium10： Impact of innovative treatments on hematopoietic stem cell transplantations
	Marcel van den Brink　 （Medicine, Memorial Sloan Kettering Cancer Center, USA） Symposium10： Impact of innovative treatments on hematopoietic stem cell transplantations “CAR T cells to prevent relapse and GVHD after allo-HCT”
	Giovanni Palladini （Amyloidosis Research and Treatment Center, Foundation“IRCCS Policlinico San Matteo”, and Department of Molecular Medicine, University of Pavia, Pavia, Italy） Symposium11： Myeloma-related disorders: from pathogenesis to new therapeutic approach
	Nelson Leung （Nephrology and Hypertension, Hematology, Mayo Clinic Rochester, USA） Symposium11： Myeloma-related disorders: from pathogenesis to new therapeutic approach
	Jonathan W. Friedberg （Wilmot Cancer Institute, University of Rochester, USA） Educational Lecture EL3-6A： Optimal induction approaches for follicular lymphoma: are we moving toward a precision approach ? “Current and future induction therapy for follicular lymphoma: moving toward a precision approach”
	Nathan Fowler （MD Anderson Cancer Center, USA） Educational Lecture EL3-6B： Treatment strategy for follicular lymphoma: are we ready to abandon chemotherapy ?
	Wichai Prayoonwiwat （Thai Society of Hematology/Phramongkutklao Hospital, Thailand） Asian Joint Panel Discussion： B-cell malignancy including multiple myeloma
	Jin Lu （Department of Hematology, peking university people’s hospital, China） Asian Joint Panel Discussion： B-cell malignancy including multiple myeloma “update data of multiple myeloma in china”
	Shang-Ju Wu （Hematology Division, National Taiwan University Hospital , Taiwan） Asian Joint Panel Discussion： B-cell malignancy including multiple myeloma “Dissecting the characteristics of CLL in Taiwan”
	Lalita Norasetthada （Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Thailand） Asian Joint Panel Discussion： B-cell malignancy including multiple myeloma “Extranodal B-cell lymphoma in Thailand”
	Wonseog Kim （Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University, School of Medicine Seoul, Korea） Asian Joint Panel Discussion： B-cell malignancy including multiple myeloma
	Sumeet Gujral （Pathology, tata memorial hospital, mumbai, India） Asian Joint Panel Discussion： B-cell malignancy including multiple myeloma “Indolent Clonal Lymphoid Proliferations”
	Michelle Poon （Department of Haematology-Oncology, NCIS, NUHS, Singapore） Asian Joint Panel Discussion： B-cell malignancy including multiple myeloma “Immunophenotypic and genetic characteristics of diffuse large B-cell lymphoma (DLBCL), and prognostic significance of cell of origin (COO) in a Southeast Asian population”